Rasagiline prevents neurodegeneration in thiamine deficient rats-a longitudinal MRI study.

Neuroprotection is a therapeutic approach for the management of neurodegenerative diseases. Experimental thiamine deficiency (TD) in rats provides a model for selective neurodegeneration accompanied by chronic oxidative deficits. Rats exhibit neurological and cognitive impairments, which can be partially reversed by thiamine administration, enabling the study of mechanisms of neurodegeneration as well as neuroprotection. In this magnetic resonance (MR) study we used various techniques to characterize the neuroprotective effects of rasagiline, a selective MAO-B inhibitor. TD was induced by a thiamine-deficient diet and daily injections of the central thiamine antagonist, pyrithiamine. Daily injections of either saline or rasagiline (3mg/kg) were also administered to untreated-TD rats and rasagiline-treated TD rats respectively. With the appearance of neurological symptoms, all injections were terminated and thiamine was restored. MRI scans were performed before induction of TD (control values), on days 10, 12 (before symptoms appear), 14 (symptomatic stage) and during the recuperation period. Both groups were assessed using in-vivo serial T2-weighted imaging and diffusion tensor imaging (DTI), from which apparent diffusion coefficient (ADC) and fractional anisotropy (FA) maps were calculated. A histopathological evaluation was correlated with the MRI analysis. Thalamic hyperintensities were significantly smaller and less severe in the rasagiline-treated TD rats. Enlargement of the lateral ventricles was significantly less pronounced in the rasagiline-treated TD group. FA values of the untreated-TD group decreased significantly in the thalamic on days 12 and 14 and in the corpus callosum on day 14. These results demonstrate significant neuroprotection by rasagiline which could have implications for clinical neurodegenerative disorders.

Neurodegeneration in thiamine deficient rats-A longitudinal MRI study.

Selective neurodegeneration accompanied by mitochondrial dysfunction characterizes neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. Thiamine deficiency (TD) in rats is a model for the study of cellular and molecular mechanisms that lead to selective neuronal loss caused by chronic oxidative deficits. Neurodegeneration in TD-rats develops over a period of 12 to 14 days and can be partially reversed by thiamine administration. The aim of this study was to characterize the in-vivo progression of neurodegeneration and the neuronal rescue processes in TD using T(2) magnetic resonance mapping and diffusion tensor imaging (DTI). Each rat was scanned prior to TD induction (day 0), before the appearance of neurological symptoms (day 10), during the symptomatic stage (days 12 and 14) and during the recuperation period (days 31 and 87). Time-dependent lesions were revealed mainly in the thalamus and the inferior colliculi. Early decrease in the fractional anisotropy (FA) was found on day 10 in the inferior colliculi and to a lesser degree in the thalamus, while the earliest detectable changes in the T(2) parameter occurred only on day 12. FA values in the thalamus remained significantly low after thiamine restoration, suggesting irreversible disarrangement and replacement of neuronal structures. While T(2) values in the frontal cortex demonstrated no lesions, FA values significantly increased on days 14 and 31. An enlargement of the lateral ventricles was observed and persevered during the recovery period. This longitudinal MRI study demonstrated that in TD MRI can detect neurodegeneration and neuronal recovery. DTI is more sensitive than T(2) mapping in the early detection of TD lesions.

Neuroprotection by rasagiline in thiamine deficient rats.

Thiamine deficiency (TD) in rats is a model of chronic impairment of oxidative metabolism leading to neuronal loss. TD rats exhibit neuropathological, behavioral and cognitive abnormalities. The aim of this study was to use this syndrome to assess the neuroprotective potential of drugs in a whole animal model. TD was produced in rats using the following protocol: thiamine deficient diet, daily injections of the central thiamine antagonist, pyrithiamine (0.5 mg/kg), and the test drugs, the selective monoamine oxidase (MAO) B inhibitors, rasagiline (1 or 3 mg/kg/day) and selegiline (2.4 or 8 mg/kg/day). Normal rats and untreated TD rats served as controls. Upon the appearance of neurological symptoms, the TD protocol was suspended, rats were transferred to a regular diet, pyrithiamine and test drug injections were terminated and rats were injected with 3 daily doses of thiamine (100 mg/kg). Neuroprotective potential was assessed by: general behavioral observations, cognitive testing using the Morris water maze and histopathological examination of the brains. Rasagiline but not selegiline significantly delayed the onset and severity of the neurological symptoms of TD. In the Morris water maze, TD-untreated rats displayed severe cognitive impairment while rasagiline-treated rats were similar to control rats and significantly different from TD-untreated rats. The effects were dose related. Selegiline treatment had no significant protective effect. TD-untreated brains displayed extensive gliotic and necrotic lesions mainly in the thalamus and posterior collicular nucleus, which were significantly reduced in the rasagiline-treated TD rats. These findings demonstrate significant neuroprotection by rasagiline with possible implications for clinical neurodegenerative disorders.

Very low-frequency heart rate variability wave amplitude and sympathetic stimulation--characterization and modeling.

The purpose of this study was to assess the relationship between very low-frequency heart rate variability (LFHR) wave amplitude and the degree of sympathetic stimulation. We developed a computerized system for the controlled increase of heart rate (HR) by isoproterenol (ISP), with which we obtained a series of stabilized HR levels in conscious freely moving rats. We found that LFHR amplitude rises gradually as a function of the average HR for each level until it reaches a point where additional increases in average HR are associated with gradual decrease in LFHR amplitude. We successfully built and fitted a model of LFHR amplitude to the experimental results. The fact that our model fits the experimental data well may suggest a possible relationship between our LFHR amplitude findings and the basic physiologic properties of the HR-ISP system inherent in our model.

Hypertension and neuronal degeneration in excised rat spinal cord studied by high-b value q-space diffusion magnetic resonance imaging.

Hypertension is one of the major risk factors of stroke and vascular dementia (VaD). We used stroke prone spontaneous hypertensive rats (SPSHRs) as a model for neuronal degeneration frequently occurring in humans with vascular disease. Recently, high b value q-space diffusion-weighted imaging (DWI) was shown to be very sensitive to the pathophysiological state of the white matter. We studied the spinal cords of SPSHR rats ex vivo after the appearance of motor impairments using diffusion anisotropy and q-space diffusion imaging (measured at a high b value of up to 1 x 10(5) s/mm(2)). The diffusion anisotropy images computed from low b value data set (b(max) approximately 2500 s/mm(2)) showed a small but statistically significant decrease (approximately 12%, P < 0.05) in the diffusion anisotropy in the spinal cords of the SPSHR group as compared to control rats. However, more significant changes were found in the high b value q-space diffusion images. The q-space displacement values in the white matter of the SPSHR group were found to be higher by more than 70% (P < 0.002) than that of the control group. These observations concurred with electron microscopy (EM) that showed significant demyelination in the spinal cords of the SPSHR group. These results seem to indicate that high b value q-space DWI might be a sensitive method for following demyelination and axonal loss associated with vascular insults.

A common origin of the very low frequency heart rate and blood pressure variability--a new insight into an old debate.

The purpose of this study was to assess the exact temporal and amplitude relationship between very low frequency heart rate variability waves and very low frequency blood pressure variability waves. We developed a computerized system based on a modified proportional-integral controller for the controlled increase of heart rate by isoproterenol. Heart rate and blood pressure were measured continuously in conscious tethered rats. Using time domain methods, we found that the very low frequency heart rate variability waves and the very low frequency blood pressure variability waves are irregular, while at the same time strikingly 1:1 synchronized with each other. In 78% of the cases, the phase between the peaks of the very low frequency heart rate variability waves and very low frequency blood pressure variability waves was negative (blood pressure leads). Their amplitudes were linearly related with a degree of hysteresis. As blood pressure went up, heart rate went down. Our results suggest with a high degree of probability that the very low frequency heart rate variability waves do not cause very low frequency blood pressure variability waves, and that these two signals are probably driven by the same autonomic nervous system controller/oscillator.